GlassScriptPhysician profile
Jobse I Lebron
NPI 1427367077
$1,091.59
in general payments reported to CMS, 2019-2025
15 companies · $116 in 2025
The $116 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $170 · 2021: $202 · 2022: $195 · 2023: $166 · 2024: $89.25 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $371.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $344.46 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $160.50 | 2019-2025 | Kisunla |
| Novartis Pharmaceuticals Corporation | $125.18 | 2021-2022 | |
| Redhill Biopharma INC. | $70.50 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.25 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.43 | 2020-2023 | Ibschek |
| Bayer Healthcare Pharmaceuticals INC. | $55.42 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $46.35 | 2021-2022 | |
| Pfizer INC. | $43.05 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $31.47 | 2024-2025 | Breztri, Airsupra |
| Xeris Pharmaceuticals, INC. | $23.74 | 2021 | |
| Nevro Corp. | $19.15 | 2022 | |
| Mylan Specialty L.P. | $18.89 | 2020 | |
| Novo Nordisk INC | $16.66 | 2023 | Ozempic, Rybelsus |
| Amgen INC. | $15.54 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jobse Lebron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.